Ripisartan
Alternative Names: UP 2696Latest Information Update: 18 Nov 2019
At a glance
- Originator UPSA
- Class Small molecules
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atherosclerosis; Coronary artery restenosis; Heart failure; Hypertension
Most Recent Events
- 08 Oct 2001 No-Development-Reported for Atherosclerosis in France (Unknown route)
- 08 Oct 2001 No-Development-Reported for Coronary artery restenosis in France (Unknown route)
- 08 Oct 2001 No-Development-Reported for Heart failure in France (Unknown route)